Archives of endocrinology and metabolism · 2026
Clinical characteristics, glycemic control & quality of life of patients using Android Artificial Pancreas System (AAPS) in Brazil.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ventura Gabriella Lopes, Messias Laryssa da Silva, Dantas Maria Eduarda Pereira, Leite Milena Oliveira, Souto Débora, Machado Maria de Lourdes Passos, Perrotti Edson, Soares Thiago Mota, Oliveira Tassia Virginia de Carvalho, Zajdenverg Lenita, Dantas Joana, Rodacki Melanie
Аннотация
OBJECTIVE: This study evaluated the safety and efficacy of the Android Artificial Pancreas System (AAPS) in Brazilians with type 1 diabetes mellitus (T1D).
SUBJECTS AND METHODS: A total of 371 participants were surveyed, including 62 AAPS users and 309 non-users. AAPS configurations included continuous glucose monitoring (CGM ), Bluetooth transmitter (MiaoMiao), and a non-automated insulin pump.
RESULTS: AAPS users had a mean Time in Range (TIR) of 78.5% ± 16.6, with HbA1c levels decreasing from 7.3% ± 1.03 to 6.5% ± 0.7 (p < 0.001). Compared to non-AAPS users, AAPS users demonstrated better glycemic control, fewer severe hypoglycemic events (p = 0.006), and improved quality of life (p < 0.0001). However, 23.08% of AAPS users had a TIR below 70%, and time in level-2 hypoglycemia exceeded recommendations.
CONCLUSION: These findings highlight AAPS as a low-cost alternative to commercial systems, with potential to expand access to automated therapy globally, particularly in resource-limited settings.
SUBJECTS AND METHODS: A total of 371 participants were surveyed, including 62 AAPS users and 309 non-users. AAPS configurations included continuous glucose monitoring (CGM ), Bluetooth transmitter (MiaoMiao), and a non-automated insulin pump.
RESULTS: AAPS users had a mean Time in Range (TIR) of 78.5% ± 16.6, with HbA1c levels decreasing from 7.3% ± 1.03 to 6.5% ± 0.7 (p < 0.001). Compared to non-AAPS users, AAPS users demonstrated better glycemic control, fewer severe hypoglycemic events (p = 0.006), and improved quality of life (p < 0.0001). However, 23.08% of AAPS users had a TIR below 70%, and time in level-2 hypoglycemia exceeded recommendations.
CONCLUSION: These findings highlight AAPS as a low-cost alternative to commercial systems, with potential to expand access to automated therapy globally, particularly in resource-limited settings.